Comparison between the Viral Illness Caused by SARS-CoV-2, Influenza Virus, Respiratory Syncytial Virus and Other Respiratory Viruses in Pediatrics

被引:3
|
作者
Brigadoi, Giulia [1 ]
Demarin, Giulia Camilla [1 ]
Boracchini, Riccardo [2 ]
Pierantoni, Luca [3 ]
Rossin, Sara [4 ]
Barbieri, Elisa [1 ]
Tirelli, Francesca [4 ]
Cantarutti, Anna [2 ]
Tempo, Gaia [5 ]
Giaquinto, Carlo [1 ]
Lanari, Marcello [3 ]
Da Dalt, Liviana [4 ]
Dona, Daniele [1 ]
机构
[1] Univ Padua, Dept Womens & Childrens Hlth, Div Pediat Infect Dis, I-35128 Padua, Italy
[2] Univ Milano Bicocca, Dept Stat & Quantitat Methods, Unit Biostat Epidemiol & Publ Hlth, Lab Healthcare Res & Pharmacoepidemiol, I-20126 Milan, Italy
[3] IRCCS Azienda Osped Univ Bologna, Pediat Emergency Unit, I-40138 Bologna, Italy
[4] Univ Padua, Pediat Emergency Dept, Dept Womens & Childrens Hlth, I-35128 Padua, Italy
[5] Fdn Policlin Univ A Gemelli IRCCS, Dept Anesthesia & Intens Care, I-00168 Rome, Italy
来源
VIRUSES-BASEL | 2024年 / 16卷 / 02期
关键词
SARS-CoV-2; COVID-19; pediatric; children; respiratory tract infections; respiratory syncytial virus; Influenza virus; COVID-19; CHILDREN; IMPACT; INFECTIONS; BURDEN;
D O I
10.3390/v16020199
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Respiratory tract infections (RTIs) are the most common infectious syndromes, primarily caused by viruses. The primary objective was to compare the illness courses between historical RTIs and recent SARS-CoV-2 infections. The study cohort consisted of RTI cases evaluated at the Pediatric Emergency Departments of Padua and Bologna, discharged or admitted with microbiologically confirmed viral RTI between 1 November 2018 and 30 April 2019 (historical period) and 1 March 2020 and 30 April 2021 (recent period). We evaluated the risk of oxygen or respiratory support, hospitalization, antibiotic therapy, and complications among different viral infections. The odds ratio (OR) and the 95% confidence intervals (CIs) were estimated through mixed-effect logistic regression models, including a random intercept on the individual and hospital. We identified 767 RTIs: 359 in the historical period compared with 408 SARS-CoV-2 infections. Infections of SARS-CoV-2 had a lower risk of being admitted (OR 0.04, 95% CI 0.03-0.07), receiving respiratory support (OR 0.19, 95% CI 0.06-0.58), needing antibiotic therapy (OR 0.35, 95% CI 0.22-0.56) and developing complications (OR 0.27, 95% CI 0.14-0.51) compared to all other viral RTIs. COVID-19 in children is clinically similar to other viral RTIs but is associated with a less severe infection course. Thus, most prevention strategies implemented for SARS-CoV-2 should still be considered during RSV and Influenza epidemics.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses
    Swets, Maaike C.
    Russell, Clark D.
    Harrison, Ewen M.
    Docherty, Annemarie B.
    Lone, Nazir
    Girvan, Michelle
    Hardwick, Hayley E.
    Investigators, Isaricc
    Visser, Leonardus G.
    Openshaw, Peter J. M.
    Groeneveld, Geert H.
    Semple, Malcolm G.
    Baillie, J. Kenneth
    LANCET, 2022, 399 (10334): : 1463 - 1464
  • [2] CONCOMITANT INFECTION OF SARS-COV-2, INFLUENZA A/B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS
    Bandarra, S.
    Gil, F.
    Neto, C.
    Monteiro, L.
    Brum, L.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 130 : S107 - S107
  • [3] Burden of Acute Respiratory Infections Caused by Influenza Virus, Respiratory Syncytial Virus, and SARS-CoV-2 with Consideration of Older Adults: A Narrative Review
    Hanage, William P.
    Schaffner, William
    INFECTIOUS DISEASES AND THERAPY, 2025, 14 (SUPPL1) : 5 - 37
  • [4] Circulation and Codetections of Influenza Virus, SARS-CoV-2, Respiratory Syncytial Virus, Rhinovirus, Adenovirus, Bocavirus, and Other Respiratory Viruses During 2022-2023 Season in Latvia
    Kampenusa, Inara
    Niedre-Otomere, Baiba
    Trofimova, Julija
    Pole, Ilva
    Pakarna, Gatis
    Savicka, Oksana
    Nikisins, Sergejs
    VIRUSES-BASEL, 2024, 16 (11):
  • [5] Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication
    Tripp, Ralph A.
    Martin, David E.
    VIRUSES-BASEL, 2022, 14 (03):
  • [6] Respiratory syncytial virus and SARS-CoV-2 coinfections in children
    Halabi, Katia C.
    Wang, Huanyu
    Leber, Amy L.
    Sanchez, Pablo J.
    Ramilo, Octavio
    Mejias, Asuncion
    PEDIATRIC PULMONOLOGY, 2022, 57 (12) : 3158 - 3160
  • [7] Respiratory syncytial virus and other respiratory viruses
    Welliver, RC
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (02) : S6 - S12
  • [8] Clinical and epidemiological characteristics of respiratory syncytial virus, SARS-CoV-2 and influenza paediatric viral respiratory infections in southwest Saudi Arabia
    Asseri, Ali Alsuheel
    Al-Qahtani, Saleh M.
    Alzaydani, Ibrahim A.
    Al-Jarie, Ahmed
    Alyazidi, Noha Saad
    Alrmelawi, Ali A.
    Alqahtani, Alya Musfer
    Alsulayyim, Rahaf S.
    Alzailaie, Ameerah K.
    Abdullah, Dhay M.
    Ali, Abdelwahid S.
    ANNALS OF MEDICINE, 2025, 57 (01)
  • [9] Detection and Differentiation of SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses by CRISPR
    Zhou, Huifen
    Tsou, Jen-Hui
    Chinthalapally, Molangur
    Liu, Hongjie
    Jiang, Feng
    DIAGNOSTICS, 2021, 11 (05)
  • [10] A Narrative Review of Key Risk Factors for Severe Illness Following SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus Infection
    Branche, Angela
    Ramesh, Mayur
    Francis, Beverly
    INFECTIOUS DISEASES AND THERAPY, 2025, 14 (SUPPL1) : 39 - 61